Salma Jabbour, MD, discusses the implications of a 4-year follow-up of the KEYNOTE-799 study of pembrolizumab and chemoradiotherapy in stage III non–small cell lung cancer.
Salma Jabbour, MD
Advertisement
Salma Jabbour, MD, is the associate director for Faculty Affairs and Development, vice chair of Clinical Research & Faculty Development, and clinical chief of Radiation Oncology at Rutgers Cancer Institute.
Articles by Salma Jabbour, MD
Advertisement
Latest Updated Articles
Nearly 4 Years Later, Pembrolizumab Plus CRT Shows Staying PowerPublished: July 4th 2024 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
